Recludix Pharma to Present at the Oppenheimer Private Life Sciences Company Showcase

By GlobeNewswire

SAN DIEGO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced that Nancy Whiting, Pharm.D., chief executive officer, and Ajay Nirula, M.D., Ph.D., president and head of research and development, will present an overview of the company at the Oppenheimer Private Life Sciences Company Showcase. The company’s presentation will be on Tuesday, September 29, 2026, at 3:15 p.m. Eastern Time.

To access the live and archived webcast of the presentation, visit the News & Events page of the company’s website at https://recludixpharma.com/news-events/#events.

About Recludix
Recludix is a clinical-stage company with leading, innovative platform approaches to discover and develop potent and selective inhibitors of challenging protein targets. The company’s management team includes industry veterans with a track record of success, including former leaders of Seagen, Blueprint Medicines, and Lilly. Recludix has developed a unique drug discovery platform that integrates custom generated DNA-encoded libraries, massively parallel determination of structure activity relationships, and a proprietary screening tool to ensure selectivity. The company is employing this approach first in the development of SH2 domain inhibitors.

Recludix is conducting a Phase 1 study of REX-8756 (also known as SAR448755), an oral inhibitor of STAT6, in a strategic development and commercialization partnership with Sanofi where Recludix has the option to participate in an equal U.S. profit/loss share. Abnormal activation of STAT6 is found in inflammatory diseases, such as atopic dermatitis, asthma, chronic obstructive pulmonary disease and chronic spontaneous urticaria.

Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs. Recludix was named a 2024 Fierce 15 biotech company. For more information, please visit the company’s website at https://recludixpharma.com.

Recludix Contacts
Matt Caldemeyer
Chief Business Officer
mcaldemeyer@recludix.com

Alexandra Santos
asantos@wheelhouselsa.com

Aljanae Reynolds
areynolds@wheelhouselsa.com


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.